Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Sleep Onset Latency
Interventions: Amber Tinted Glasses, Clear Glasses, Smart Lightbulbs; Device
Lead sponsor: University of Arizona; Other
Eligibility: 60 Months to 83 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Breast Cancer
Interventions: Physical Evaluation, Dual-energy X-ray absorptiometry scans, Trabecular Bone Score; Other · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Geographic Atrophy of the Macula
Interventions: GAL-101, Placebo; Drug
Lead sponsor: Galimedix Therapeutics Inc; Industry
Eligibility: 55 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland

Conditions: Crohn Disease
Interventions: Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan; Drug · Procedure · Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 13 Years to 28 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Alcohol Use Disorder, Alcohol Use Disorder (AUD)
Interventions: STAR; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Lymphocytic Leukemia
Interventions: [U-13C]glucose, [13C5]glutamine; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Vestibular Diseases, Vestibular Disorder, Alzheimer Disease
Interventions: Vestibular physical therapy, Active control; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-small Cell Lung Cancer
Interventions: Osimertinib, Datopotamab Deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 37
States / cities: Fountain Valley, California • Los Alamitos, California • Los Angeles, California + 32 more

Conditions: Breast Cancer, Gynecologic Cancers, Mitochondrial Function
Interventions: Not listed
Lead sponsor: University of South Carolina; Other
Eligibility: 20 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Vaccine Response
Interventions: Live Attenuated Yellow Fever 17D Vaccine, Quadrivalent seasonal influenza vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Posttraumatic Stress Disorder
Interventions: Active Intermittent theta burst stimulation, Sham Intermittent theta burst stimulation; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Albuquerque, New Mexico

Conditions: Chronic Pain Patients, Medical Cannabis Users
Interventions: Cognitive testing, Task-based fMRI measure of face-name and verbal learning; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 30 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Inflammatory Bowel Disease
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Cardiovascular Diseases, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Coronary Artery Disease
Interventions: CT(Computed Tomography) guided Percutaneous Coronary Intervention, IVUS (Intravascular Ultrasound) guided Percutaneous Coronary Intervention; Device
Lead sponsor: Fundación EPIC; Other
Eligibility: 18 Years to 85 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Jersey City, New Jersey + 1 more

Conditions: Colorectal Cancer
Interventions: ONO-4578, Opdivo®, Oxaliplatin, 5-Fluorouracil, Bevacizumab, Leucovorin; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Lone Tree, Colorado + 8 more

Conditions: Melanoma Stage IV, Solid Tumor
Interventions: GIM-531, Anti-PD-1 monoclonal antibody; Drug
Lead sponsor: Georgiamune Inc; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Scottsdale, Arizona • Bakersfield, California • Fullerton, California + 8 more

Conditions: Dental Sealant, Sealant Retention
Interventions: Ultradent Ultra Seal XT Plus; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 5 Years to 14 Years
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophageal Adenocarcinoma
Interventions: Seattle protocol, WATS3D brushings; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 2,298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Gilbert, Arizona • Los Angeles, California • Oakland, California + 11 more

Conditions: Advanced Malignant Solid Tumor, Solid Tumor Cancer
Interventions: PLT012; Drug
Lead sponsor: Pilatus Biosciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Dallas, Texas • Houston, Texas

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Active repetitive TMS, Sham repetitive TMS; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Tetraplegia, Locked-in Syndrome, Brainstem Stroke, Amyotrophic Lateral Sclerosis
Interventions: Surgical implantation of CortiCom system; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 22 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers
Interventions: AVZO-1418, Combination Agent 1, Combination Agent 2; Drug
Lead sponsor: Avenzo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 19
States / cities: Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Triple Negative Breast Cancer
Interventions: Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide, Olaparib, Capecitabine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lafora Disease
Interventions: ION283; Genetic
Lead sponsor: Berge Minassian; Other
Eligibility: 10 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Circadian Light Exposure Adjustment for Restfulness

Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Stem Cell Transplantation in Crohn's Disease

Optimizing Smart Technology for Addiction Recovery

In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)

Vestibular Therapy in Alzheimer's Disease

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients

Durability of Vaccine Responses

Multimodal Image Analysis and Guidance of Neuromodulation for Trauma-Related Symptoms

Medical Cannabis and Behavior

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease

A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

COES: Curing Order Effects on Sealants

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

ADHD PreSMA Response Inhibition Therapy

Investigation on the Cortical Communication (CortiCom) System

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease